Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Shares Issued (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Shares Issued for 7 consecutive years, with -$2.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Issued fell 104.65% year-over-year to -$2.9 million, compared with a TTM value of $66.3 million through Jun 2025, up 6667.04%, and an annual FY2024 reading of $64.5 million, changed N/A over the prior year.
  • Shares Issued was -$2.9 million for Q3 2025 at Zevra Therapeutics, down from $2.9 million in the prior quarter.
  • Across five years, Shares Issued topped out at $63.4 million in Q3 2024 and bottomed at -$5.9 million in Q4 2021.
  • Average Shares Issued over 5 years is $6.8 million, with a median of $137000.0 recorded in 2022.
  • Peak annual rise in Shares Issued hit 38274.7% in 2024, while the deepest fall reached 142.77% in 2024.
  • Year by year, Shares Issued stood at -$5.9 million in 2021, then soared by 101.82% to $108000.0 in 2022, then tumbled by 253.7% to -$166000.0 in 2023, then soared by 38274.7% to $63.4 million in 2024, then tumbled by 104.65% to -$2.9 million in 2025.
  • Business Quant data shows Shares Issued for ZVRA at -$2.9 million in Q3 2025, $2.9 million in Q2 2025, and $63.4 million in Q3 2024.